IBio Initiated at Buy by Chardan Capital
IBio Initiated at Buy by Chardan Capital
IBio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/28/2024 121.24% Chardan Capital → $5 Initiates Coverage On → Buy 02/16/2023 — JMP Securities Downgrade
Ibio Inc: Chardan Capital Markets launches report with a buy rating; target price is $5
Ibio Inc: Chardan Capital Markets launches report with a buy rating; target price is $5
Express News | Ibio Inc : Chardan Capital Markets Initiates Coverage With Buy Rating; Target Price $5
Chardan Research Starts IBio With Buy Rating, $5 Price Target
Chardan Research Starts iBio With Buy Rating, $5 Price Target.
US and Europe speed up procurement of bird flu vaccine to deal with potential pandemic threat
The United States and Europe are taking steps to purchase or produce H5N1 avian influenza vaccines to protect at-risk poultry and dairy farm workers, vets, and laboratory technicians.
Avian flu cases spur retail investors to buy vaccine stocks
The increase in cases of avian influenza triggered investors to rush to buy vaccine stocks, and the stock prices of companies such as CureVac, Novavax, and Moderna soared. Experts recommend investing cautiously, as the development of the epidemic is uncertain.
IBio Reports Q3 Results
iBio Inc | 10-Q: Quarterly report
IBio Q3 EPS $(0.71) Up From $(9.53) YoY
iBio (AMEX:IBIO) reported quarterly losses of $(0.71) per share. This is a 92.55 percent increase over losses of $(9.53) per share from the same period last year.
IBio 3Q Rev $0 >IBIO
IBio 3Q Rev $0 >IBIO
Press Release: IBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update -- Strengthened cash position with investment by healthcare specialist investors -- Expanding into c
The coronavirus hasn't disappeared yet! A new “FlIRt variant family” is spreading in the US...
① According to CDC data, the main variant of transmission in the US today is the “FlIRT” family, led by KP.2; ② KP.2 accounts for 25%; ③ medical experts warn that fLiRT has a more obvious transmission advantage and may trigger a new wave of COVID-19.
IBio Files Prospectus Relates To Resale From Time To Time Of Up To 10.6M Shares Of Common Stock By Selling Stockholders
IBio Files Prospectus Relates To Resale From Time To Time Of Up To 10.6M Shares Of Common Stock By Selling Stockholders
IBio Inc. Raises $15M in Private Placement and Issues Warrants
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) stock rose 289.1% to $18.48 during Friday's pre-market session. The market value of their outstanding shares is at $14.8 million. Xilio Therapeutics (NASDAQ:XLO
IBio, Mesoblast, Kodiak Sciences Among Healthcare Movers
Top Midday Gainers
iBio's (IBIO) shares were up 211% amid heavy trading Wednesday, a day after the company said it signed a securities purchase agreement for a private investment in public equity financing with expected
SMR, GCTS and GSIW Among Mid-day Movers
IBio Climbs After AI-led Drug Discovery Deal